{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T02:51:02Z","timestamp":1776307862788,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Somatostatin receptor ligands (SRL) are the first-line medical treatment for acromegaly. Gallbladder alterations are one of most important SRL side effect, but according to some authors growth hormone hypersecretion itself is a risk factor for gallstones. This single center, longitudinal retrospective study evaluated the incidence and the predictors of biliary adverse events (BAE) in acromegaly during SRL therapy and their response to ursodeoxycholic acid (UDCA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>91 acromegaly patients with indication to SRL were enrolled. Evaluations of acromegaly activity (GH, IGF-I, IGF-I\/ULN) and metabolic profile were collected before starting treatment, yearly during follow-up and at BAE onset. In patients developing BAE we searched for predictors of UDCA effectiveness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>61.5% of patients developed BAE (58.9% cholelithiasis; 41.1% only sludge). IGF-I and IGF-I\/ULN proved to be positive predictor of BAE, which occur about 5\u00a0years after SRL starting. None of metabolic markers proved to be associated with BAE. Only five patients (5.5%) underwent cholecystectomy for symptomatic cholelithiasis. 71% of patients started UDCA treatment, achieving regression of BAE in 60% of cases (88% in patients developing only sludge and 30% in patients affected by cholelithiasis, p\u2009&lt;\u20090.001). BMI and obesity were negative predictors of UDCA efficacy. In 50% of the subjects BAE resolved after 36\u00a0months of therapy with a lower rate if cholelithiasis was present.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Biliary stone disease is a frequent SRL adverse event, although it is often symptomless. Ultrasound follow-up mainly in the first 5\u00a0years of therapy, early UDCA starting and proper lifestyle represent a valid strategy in their detection and management.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11102-020-01102-7","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T03:04:22Z","timestamp":1604891062000},"page":"242-251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9951-1796","authenticated-orcid":false,"given":"N.","family":"Prencipe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Cuboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Parasiliti-Caprino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Berton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. M.","family":"Fenoglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Gasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Grottoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"1102_CR1","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1517\/14740338.2015.1059817","volume":"14","author":"LF Grasso","year":"2015","unstructured":"Grasso LF, Auriemma RS, Pivonello R, Colao A (2015) Adverse events associated with somatostatin analogs in acromegaly. Expert Opin Drug Saf 14:1213\u20131226. https:\/\/doi.org\/10.1517\/14740338.2015.1059817","journal-title":"Expert Opin Drug Saf"},{"key":"1102_CR2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJM199302113280608","volume":"328","author":"DE Johnston","year":"1993","unstructured":"Johnston DE, Kaplan MM (1993) Pathogenesis and treatment of gallstones. N Engl J Med 328:412\u2013421. https:\/\/doi.org\/10.1056\/NEJM199302113280608","journal-title":"N Engl J Med"},{"key":"1102_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000199408","volume":"36","author":"B Lembcke","year":"1987","unstructured":"Lembcke B, Creutzfeldt W, Schleser S et al (1987) Effect of the somatostatin analogue Sandostatin (SMS 201\u2013995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 36:108\u2013124. https:\/\/doi.org\/10.1159\/000199408","journal-title":"Digestion"},{"key":"1102_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1046\/j.1365-2036.2001.00924.x","volume":"15","author":"A Moschetta","year":"2001","unstructured":"Moschetta A, Stolk MFJ, Rehfeld JF et al (2001) Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR. Aliment Pharmacol Ther 15:181\u2013185. https:\/\/doi.org\/10.1046\/j.1365-2036.2001.00924.x","journal-title":"Aliment Pharmacol Ther"},{"key":"1102_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/gut.2004.048074","volume":"54","author":"AF Hofmann","year":"2005","unstructured":"Hofmann AF (2005) Increased deoxycholic acid absorption and gall stones in acromegalic patients treated with octreotide: more evidence for a connection between slow transit constipation and gall stones. Gut 54:575\u2013578. https:\/\/doi.org\/10.1136\/gut.2004.048074","journal-title":"Gut"},{"key":"1102_CR6","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1210\/jcem.80.9.7673422","volume":"80","author":"CB Newman","year":"1995","unstructured":"Newman CB, Melmed S, Snyder PJ et al (1995) Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients\u2014a clinical research center study. J Clin Endocrinol Metab 80:2768\u20132775. https:\/\/doi.org\/10.1210\/jcem.80.9.7673422","journal-title":"J Clin Endocrinol Metab"},{"key":"1102_CR7","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1517\/14740330903379525","volume":"8","author":"J Bornschein","year":"2009","unstructured":"Bornschein J, Drozdov I, Malfertheiner P (2009) Octreotide LAR: safety and tolerability issues. Expert Opin Drug Saf 8:755\u2013768. https:\/\/doi.org\/10.1517\/14740330903379525","journal-title":"Expert Opin Drug Saf"},{"key":"1102_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.dld.2018.09.013","volume":"51","author":"N Brighi","year":"2019","unstructured":"Brighi N, Lamberti G, Maggio I et al (2019) Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. a retrospective observational study. Dig Liver Dis 51:689\u2013694. https:\/\/doi.org\/10.1016\/j.dld.2018.09.013","journal-title":"Dig Liver Dis"},{"key":"1102_CR9","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/hep.20654","volume":"41","author":"D Katsika","year":"2005","unstructured":"Katsika D, Grjibovski A, Einarsson C et al (2005) Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology 41:1138\u20131143. https:\/\/doi.org\/10.1002\/hep.20654","journal-title":"Hepatology"},{"key":"1102_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.bpg.2014.07.013","volume":"28","author":"L Bonfrate","year":"2014","unstructured":"Bonfrate L, Wang DQ-H, Garruti G, Portincasa P (2014) Obesity and the risk and prognosis of gallstone disease and pancreatitis. Best Pract Res Clin Gastroenterol 28:623\u2013635. https:\/\/doi.org\/10.1016\/j.bpg.2014.07.013","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"1102_CR11","doi-asserted-by":"publisher","unstructured":"Pak M, Lindseth G (2016) Risk factors for cholelithiasis. Gastroenterol Nurs 39:297\u2013309. https:\/\/doi.org\/10.1097\/SGA.0000000000000235","DOI":"10.1097\/SGA.0000000000000235"},{"key":"1102_CR12","doi-asserted-by":"publisher","first-page":"16024","DOI":"10.1038\/nrdp.2016.24","volume":"2","author":"F Lammert","year":"2016","unstructured":"Lammert F, Gurusamy K, Ko CW et al (2016) Gallstones. Nat Rev Dis Primers 2:16024. https:\/\/doi.org\/10.1038\/nrdp.2016.24","journal-title":"Nat Rev Dis Primers"},{"key":"1102_CR13","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1080\/00365521.2016.1182583","volume":"51","author":"DM Shabanzadeh","year":"2016","unstructured":"Shabanzadeh DM, S\u00f8rensen LT, J\u00f8rgensen T (2016) Determinants for gallstone formation\u2014a new data cohort study and a systematic review with meta-analysis*. Scand J Gastroenterol 51:1239\u20131248. https:\/\/doi.org\/10.1080\/00365521.2016.1182583","journal-title":"Scand J Gastroenterol"},{"key":"1102_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1365-2265.1994.tb03938.x","volume":"40","author":"M Montini","year":"1994","unstructured":"Montini M, Gianola D, Paganl MD et al (1994) Cholelithiasis and acromegaly: therapeutic strategies. Clin Endocrinol 40:401\u2013406. https:\/\/doi.org\/10.1111\/j.1365-2265.1994.tb03938.x","journal-title":"Clin Endocrinol"},{"key":"1102_CR15","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/gut.2003.028431","volume":"54","author":"LA Thomas","year":"2005","unstructured":"Thomas LA, Veysey MJ, Murphy GM et al (2005) Octreotide induced prolongation of colonic transit increases faecal anaerobic bacteria, bile acid metabolising enzymes, and serum deoxycholic acid in patients with acromegaly. Gut 54:630\u2013635. https:\/\/doi.org\/10.1136\/gut.2003.028431","journal-title":"Gut"},{"key":"1102_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/gut.34.2.270","volume":"34","author":"SM Catnach","year":"1993","unstructured":"Catnach SM, Anderson JV, Fairclough PD et al (1993) Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly. Gut 34:270\u2013273","journal-title":"Gut"},{"key":"1102_CR17","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/BF03346419","volume":"31","author":"R Attanasio","year":"2008","unstructured":"Attanasio R, Mainolfi A, Grimaldi F et al (2008) Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients. J Endocrinol Investig 31:704\u2013710. https:\/\/doi.org\/10.1007\/BF03346419","journal-title":"J Endocrinol Investig"},{"key":"1102_CR18","doi-asserted-by":"publisher","unstructured":"(2016) EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 65:146\u2013181. https:\/\/doi.org\/10.1016\/j.jhep.2016.03.005","DOI":"10.1016\/j.jhep.2016.03.005"},{"key":"1102_CR19","doi-asserted-by":"crossref","unstructured":"Lee SP, Maher K, Nicholls JF (1988) Origin and fate of biliary sludge. Gastroenterology 94:170\u2013176","DOI":"10.1016\/0016-5085(88)90626-9"},{"key":"1102_CR20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1542-3565(05)00369-1","volume":"3","author":"CW Ko","year":"2005","unstructured":"Ko CW, Schulte SJ, Lee SP (2005) Biliary sludge is formed by modification of hepatic bile by the gallbladder mucosa. Clin Gastroenterol Hepatol 3:672\u2013678. https:\/\/doi.org\/10.1016\/S1542-3565(05)00369-1","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1102_CR21","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.bpg.2006.03.007","volume":"20","author":"C J\u00fcngst","year":"2006","unstructured":"J\u00fcngst C, Kullak-Ublick GA, J\u00fcngst D (2006) Microlithiasis and sludge. Best Pract Res Clin Gastroenterol 20:1053\u20131062. https:\/\/doi.org\/10.1016\/j.bpg.2006.03.007","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"1102_CR22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P et al (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99:791\u2013799. https:\/\/doi.org\/10.1210\/jc.2013-2480","journal-title":"J Clin Endocrinol Metab"},{"key":"1102_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T et al (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2:875\u2013884. https:\/\/doi.org\/10.1016\/S2213-8587(14)70169-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1102_CR24","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.3748\/wjg.v19.i31.5029","volume":"19","author":"MPL Guarino","year":"2013","unstructured":"Guarino MPL, Cocca S, Altomare A et al (2013) Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol 19:5029\u20135034. https:\/\/doi.org\/10.3748\/wjg.v19.i31.5029","journal-title":"World J Gastroenterol"},{"key":"1102_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1586\/17474124.2016.1109445","volume":"10","author":"P Portincasa","year":"2016","unstructured":"Portincasa P, Di Ciaula A, de Bari O et al (2016) Management of gallstones and its related complications. Expert Rev Gastroenterol Hepatol 10:93\u2013112. https:\/\/doi.org\/10.1586\/17474124.2016.1109445","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1102_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1017\/S136898009900021X","volume":"2","author":"M Tseng","year":"1999","unstructured":"Tseng M, Everhart JE, Sandler RS (1999) Dietary intake and gallbladder disease: a review. Public Health Nutr 2:161\u2013172. https:\/\/doi.org\/10.1017\/S136898009900021X","journal-title":"Public Health Nutr"},{"key":"1102_CR27","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-020-01102-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-020-01102-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-020-01102-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T03:21:24Z","timestamp":1615951284000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-020-01102-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1102"],"URL":"https:\/\/doi.org\/10.1007\/s11102-020-01102-7","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]},"assertion":[{"value":"23 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflicts of interest that might be perceived as influencing the impartiality of the reported research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict on interest"}},{"value":"The study was conducted in accordance with guidelines in the Declaration of Helsinki. Approved from the Ethical Committee of \u201cCitt\u00e0 della Salute e della Scienza\u201d University Hospital of Turin was obtained and all patients provided their written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}